Aster DM Quality Care Ltd, formed after the merger with Quality Care India, has received a 'BUY' rating from Prabhudas Lilladher with a target price of ₹920. While operational profit grew 30%, overall net profit dropped 81% due to one-time merger costs. Investors are now weighing the potential of the new healthcare giant against the challenges of integrating two large operations.
Aster DM Quality Care Ltd is catching investor attention following its recent merger with Quality Care India Ltd, which became effective on July 1, 2026. Brokerage firm Prabhudas Lilladher has initiated coverage on the company with a 'BUY' rating and a target price of ₹920. This move follows the official name change and business integration, which creates the third-largest healthcare provider in India, operating over 10,800 beds across 28 cities.
The company’s performance in the first quarter of fiscal year 2027 shows a mix of strong operational growth and temporary profit pressure. Consolidated revenue grew by 20% compared to the same period last year, reaching ₹2,597 crore. Operating profit, or EBITDA, also performed well, rising 30% to ₹576 crore. This indicates that the core business is operating efficiently, with EBITDA margins improving by 170 basis points to 22.2%.
Despite the strong revenue and operating profit, the net profit fell significantly by 81.2% to ₹16.1 crore. This sharp decline is primarily linked to one-time charges associated with the merger process, rather than a decline in the core business. Investors should understand that such non-recurring expenses are common during large corporate restructurings, as companies often incur costs to consolidate systems, legal frameworks, and operations.
The primary thesis behind the positive brokerage outlook is the expectation of cost savings and improved efficiency resulting from the merger. As the combined entity stabilizes, analysts are looking for consistent margin expansion and better utilization of hospital beds. The merger is expected to allow the company to achieve greater economies of scale, potentially improving profitability over the long term as the new structure matures.
However, there are risks that investors should carefully monitor. The most immediate challenge is the successful integration of the two companies. Mixing different operational cultures, digital systems, and management processes takes time and can lead to financial fluctuations in the coming quarters. Additionally, the Indian healthcare sector remains highly competitive. The company will need to balance its aggressive expansion of new beds with the need to maintain stable margins, especially as the industry faces pressure from rising operational costs and competitive pricing.
The path ahead will depend on how quickly the company can move past these one-time merger costs and demonstrate sustained earnings growth. The next important update for investors will be the upcoming quarterly results, which will likely show whether the expected operational synergies are starting to reflect in the bottom line and how effectively the new management is integrating the Quality Care assets into the wider Aster network.